Scancell Holdings plc
SCLP.LDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Q1 2027
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
SCIB1 or iSCIB1+ DNA vaccine
Malignant Melanoma
Modi-1 Moditope
Triple Negative Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SCIB1 or iSCIB1+ DNA vaccine | Phase 2 | Malignant Melanoma | - | - |
Modi-1 Moditope | Phase 2 | Triple Negative Breast Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Scancell Holdings plc's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Scancell Holdings plc's (SCLP.L) pipeline across Phase 2. Its lead program is SCIB1 or iSCIB1+ DNA vaccine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Scancell Holdings plc's next FDA catalyst?→
Scancell Holdings plc's (SCLP.L) next tracked catalyst is a Phase 2 expected July 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SCLP.L biotech catalysts?→
Add SCLP.L to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Scancell Holdings plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.